Boston Partners reduced its position in Johnson & Johnson (NYSE:JNJ) by 21.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,680,532 shares of the company’s stock after selling 2,311,470 shares during the quarter. Johnson & Johnson comprises about 1.5% of Boston Partners’ investment portfolio, making the stock its 6th biggest position. Boston Partners owned 0.32% of Johnson & Johnson worth $1,148,348,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. State Street Corp raised its position in Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after purchasing an additional 6,656,371 shares during the period. Harbour Capital Advisors LLC raised its position in Johnson & Johnson by 13,327.8% in the second quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock valued at $18,909,000 after purchasing an additional 2,482,843 shares during the period. Canada Pension Plan Investment Board raised its position in Johnson & Johnson by 33.9% in the second quarter. Canada Pension Plan Investment Board now owns 4,696,566 shares of the company’s stock valued at $621,309,000 after purchasing an additional 1,189,900 shares during the period. Bank of Nova Scotia raised its position in Johnson & Johnson by 94.5% in the first quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock valued at $145,914,000 after purchasing an additional 569,313 shares during the period. Finally, Oppenheimer Asset Management Inc. purchased a new position in Johnson & Johnson in the first quarter valued at about $65,598,000. 65.61% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Shares Sold by Boston Partners” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/24/johnson-johnson-jnj-shares-sold-by-boston-partners.html.
Several research firms have commented on JNJ. Citigroup Inc. raised their price objective on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Monday, October 23rd. Vetr raised Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price objective on the stock in a research report on Monday, October 30th. Leerink Swann reissued an “outperform” rating and issued a $165.00 price objective (up from $150.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Royal Bank Of Canada raised their price objective on Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a research report on Wednesday, October 18th. Finally, Stifel Nicolaus raised their price objective on Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $143.70.
Shares of Johnson & Johnson (JNJ) opened at $137.29 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. The firm has a market capitalization of $368,832.31, a PE ratio of 19.23, a PEG ratio of 2.79 and a beta of 0.82. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $144.35.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $1.68 earnings per share. sell-side analysts predict that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.45%. Johnson & Johnson’s dividend payout ratio is presently 58.33%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.